Abstract
Clinical adoption of machine learning (ML) in medical imaging is limited by the lack of interpretability. To address this, we present understandable post-hoc artificial intelligence reports (UPhAIR), a pipeline designed to generate transparent, evidence-based explanations by combining Shapley additive explanation (SHAP) analysis with retrieval-augmented generation (RAG) and large language models (LLMs). We trained 12 Classifiers to predict Isocitrate dehydrogenase (IDH) mutation status in glioma using radiomics and clinical features. SHAP values were used to identify key contributors to each prediction. Domain literature was collected from three sources and indexed within a RAG framework. Relevant papers were retrieved using Facebook AI similarity search (FAISS) vector similarity search and provided to Google Gemini 2.5 Pro to generate concise, reference-supported explanations for each feature. The model achieved a best AUC of 0.90±0.02 on a 5-fold cross-validation using an extreme gradient boosting (XGBoost) Classifier and a hold-out test AUC of 0.86. In a case study of a single patient excluded from training, the model correctly predicted the patient to be IDH-wildtype glioma, and SHAP identified MGMT status, age, and three radiomic features as the most influential features. UPhAIR produced a structured report combining SHAP visualizations with LLM-generated summaries grounded in scientific evidence. UPhAIR provides a practical, model-agnostic framework that enhances ML interpretability in clinical settings, helping bridge the gap between black-box AI and real-world medical decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Publicly available T1-weighted MRI data and tumor segmentations from the University of Pennsylvania (UPenn) and University of California, San Francisco (UCSF) glioma cohorts available through The Cancer Imaging Archive (TCIA). https://www.cancerimagingarchive.net/collection/upenn-gbm/ https://www.cancerimagingarchive.net/collection/ucsf-pdgm/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at The Cancer Imaging Archive (TCIA).
